COVID-19: impact on blood and transfusion services
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.25758/set.2265 |
Resumo: | A novel coronavirus emerged with an exponential and universal cycle of infection, carrying great morbidity and mortality rate. Since the patients suffer from the severe acute respiratory syndrome, the new virus designated as SARS-CoV-2, caused an outbreak and the pronouncement of a pandemic state, forcing people into isolation. The disease named Coronavirus disease 2019 (COVID-19) led to a drastic decline in blood supply and a new order of clinical transfusion proceedings management. The Portuguese Blood and Transplantation Institute with the other national responsible organizations formulated a normative contingency plan, in order to ensure and maintain a safe blood component support to all hospital requests. Regardless of the safety policies applied systematically in the transfusion process, such as routine nucleic acid tests in all donations, leukoreduction and pathogenic inactivation of blood components, the incomplete knowledge about the epidemiology and pathogenicity of SARS-CoV-2 suggests the precautionary principle. This lesson learned from previous outbreaks is a mandatory instruction in the transfusion medicine sector. Assuming the absence of vaccines and specific medication, reference laboratories of Blood and Transplantation Centers, Blood Functional Area, are intensively tagging the identification and screening of potential donors COVID-19 convalescent plasma as an alternative therapy. |
id |
RCAP_268030f9f713b30aaacad24f8862ea9e |
---|---|
oai_identifier_str |
oai:journals.ipl.pt:article/570 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
COVID-19: impact on blood and transfusion servicesCOVID-19: impacto nos serviços de sangue e de medicina transfusionalCOVID-19Medicina transfusionalPlasma convalescenteServiços de sangueCOVID-19Transfusion medicineConvalescent plasmaBlood bankA novel coronavirus emerged with an exponential and universal cycle of infection, carrying great morbidity and mortality rate. Since the patients suffer from the severe acute respiratory syndrome, the new virus designated as SARS-CoV-2, caused an outbreak and the pronouncement of a pandemic state, forcing people into isolation. The disease named Coronavirus disease 2019 (COVID-19) led to a drastic decline in blood supply and a new order of clinical transfusion proceedings management. The Portuguese Blood and Transplantation Institute with the other national responsible organizations formulated a normative contingency plan, in order to ensure and maintain a safe blood component support to all hospital requests. Regardless of the safety policies applied systematically in the transfusion process, such as routine nucleic acid tests in all donations, leukoreduction and pathogenic inactivation of blood components, the incomplete knowledge about the epidemiology and pathogenicity of SARS-CoV-2 suggests the precautionary principle. This lesson learned from previous outbreaks is a mandatory instruction in the transfusion medicine sector. Assuming the absence of vaccines and specific medication, reference laboratories of Blood and Transplantation Centers, Blood Functional Area, are intensively tagging the identification and screening of potential donors COVID-19 convalescent plasma as an alternative therapy.Assiste-se à emergência de um novo coronavírus com um ciclo de infeção exponencial e universal e elevadas taxas de morbilidade e mortalidade. Designado como SARS-CoV-2 e dada a sintomatologia dos doentes com défice respiratório severo e pneumonia grave, o novo vírus obrigou à declaração de pandemia, forçando medidas de confinamento das populações. A doença originada pela infeção designada por Coronavirus disease 2019 (COVID-19) resultou em todos os países numa drástica diminuição do número de dadores de sangue disponíveis, por estarem infetados ou em confinamento ou ainda devido ao aumento da taxa de reprovação para prevenir o risco da dádiva de sangue por indivíduos com infeção, mas assintomáticos. O Instituto Português do Sangue e da Transplantação, em parceria com os outros organismos nacionais responsáveis, de imediato formulou um plano de contingência com caráter normativo de forma a garantir e manter um suporte terapêutico seguro de componentes sanguíneos em todas as solicitações hospitalares. Independentemente das políticas de segurança aplicadas de forma sistemática no processo transfusional, como a realização dos testes de ácidos nucleicos em todas as dádivas, a desleucocitação e a inativação patogénica dos componentes sanguíneos, até que haja mais conhecimento sobre a epidemiologia e patogenicidade do SARS-CoV-2 impõe-se no setor da medicina transfusional o princípio da precaução, lição aprendida desde há anos face aos surtos anteriores. Neste momento, os laboratórios de referência dos Centros de Sangue e da Transplantação, Área Funcional do Sangue, trabalham intensamente na identificação e rastreio dos potenciais dadores de plasma convalescente COVID-19 como opção terapêutica, tendo em conta a ausência atual de vacinas ou medicação específica.Escola Superior de Tecnologia da Saúde de Lisboa (Instituto Politécnico de Lisboa)2022-08-24info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.25758/set.2265oai:journals.ipl.pt:article/570Saúde e Tecnologia; No. T3 (2020): Nº temático - COVID-19; e22-e28Saúde & Tecnologia; N.º T3 (2020): Nº temático - COVID-19; e22-e281646-9704reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://journals.ipl.pt/stecnologia/article/view/570https://doi.org/10.25758/set.2265https://journals.ipl.pt/stecnologia/article/view/570/497Direitos de Autor (c) 2022 Saúde & Tecnologiainfo:eu-repo/semantics/openAccessLeitão, Céu2022-12-20T10:58:56Zoai:journals.ipl.pt:article/570Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:21:23.425870Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
COVID-19: impact on blood and transfusion services COVID-19: impacto nos serviços de sangue e de medicina transfusional |
title |
COVID-19: impact on blood and transfusion services |
spellingShingle |
COVID-19: impact on blood and transfusion services Leitão, Céu COVID-19 Medicina transfusional Plasma convalescente Serviços de sangue COVID-19 Transfusion medicine Convalescent plasma Blood bank |
title_short |
COVID-19: impact on blood and transfusion services |
title_full |
COVID-19: impact on blood and transfusion services |
title_fullStr |
COVID-19: impact on blood and transfusion services |
title_full_unstemmed |
COVID-19: impact on blood and transfusion services |
title_sort |
COVID-19: impact on blood and transfusion services |
author |
Leitão, Céu |
author_facet |
Leitão, Céu |
author_role |
author |
dc.contributor.author.fl_str_mv |
Leitão, Céu |
dc.subject.por.fl_str_mv |
COVID-19 Medicina transfusional Plasma convalescente Serviços de sangue COVID-19 Transfusion medicine Convalescent plasma Blood bank |
topic |
COVID-19 Medicina transfusional Plasma convalescente Serviços de sangue COVID-19 Transfusion medicine Convalescent plasma Blood bank |
description |
A novel coronavirus emerged with an exponential and universal cycle of infection, carrying great morbidity and mortality rate. Since the patients suffer from the severe acute respiratory syndrome, the new virus designated as SARS-CoV-2, caused an outbreak and the pronouncement of a pandemic state, forcing people into isolation. The disease named Coronavirus disease 2019 (COVID-19) led to a drastic decline in blood supply and a new order of clinical transfusion proceedings management. The Portuguese Blood and Transplantation Institute with the other national responsible organizations formulated a normative contingency plan, in order to ensure and maintain a safe blood component support to all hospital requests. Regardless of the safety policies applied systematically in the transfusion process, such as routine nucleic acid tests in all donations, leukoreduction and pathogenic inactivation of blood components, the incomplete knowledge about the epidemiology and pathogenicity of SARS-CoV-2 suggests the precautionary principle. This lesson learned from previous outbreaks is a mandatory instruction in the transfusion medicine sector. Assuming the absence of vaccines and specific medication, reference laboratories of Blood and Transplantation Centers, Blood Functional Area, are intensively tagging the identification and screening of potential donors COVID-19 convalescent plasma as an alternative therapy. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-08-24 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.25758/set.2265 oai:journals.ipl.pt:article/570 |
url |
https://doi.org/10.25758/set.2265 |
identifier_str_mv |
oai:journals.ipl.pt:article/570 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://journals.ipl.pt/stecnologia/article/view/570 https://doi.org/10.25758/set.2265 https://journals.ipl.pt/stecnologia/article/view/570/497 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2022 Saúde & Tecnologia info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2022 Saúde & Tecnologia |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Escola Superior de Tecnologia da Saúde de Lisboa (Instituto Politécnico de Lisboa) |
publisher.none.fl_str_mv |
Escola Superior de Tecnologia da Saúde de Lisboa (Instituto Politécnico de Lisboa) |
dc.source.none.fl_str_mv |
Saúde e Tecnologia; No. T3 (2020): Nº temático - COVID-19; e22-e28 Saúde & Tecnologia; N.º T3 (2020): Nº temático - COVID-19; e22-e28 1646-9704 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130660455055360 |